The present invention is concerned with indolin-2-one and l,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula (I) wherein Ar1 is phenyl, pyridinyl or pyrimidinyl Ar2 is a 5 or 6 membered heteroaryl group, containing 2 or 3 heteroatoms, selected from N, O or S R1 is hydrogen, lower alkyl, halogen or lower alkoxy R2 is hydrogen or lower alkyl R3 is hydrogen, lower alkyl, lower alkyl substituted by hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl, pyrimidinyl, which rings may optionally substituted by lower alkyl, or is -(CH2)3-S(O)2-cyclopropyl X is CH or N n is 1 or 2 as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof, for use in the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimers disease, autism, Parkinsons disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.La présente invention concerne des dérivés dindolin-2-one et de 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one de formule générale (I), dans laquelle Ar1 représente phényle, pyridinyle ou pyrimidinyle Ar2 représente un groupe hétéroaryle à 5 ou 6 chaînons, contenant 2 ou 3 hétéroatomes choisis parmi N, O ou S R1 représente hydrogène, alkyle inférieur, halogène ou alcoxy inférieur R2 représente hydrogène ou alkyle inférieur R3 représente hydrogène, alkyle inférieur, alkyle inférieur substitué par hydroxy, cycloalkyle, oxétan-3-yle, pyridinyle, imidazolyle, pyrazolyle, pyrimidinyle, lesquels cycles peuvent éventuellement être substitués par alkyle inférieur,
